

## Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <u>Alnylam Pharmaceuticals</u>, <u>Inc.</u> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 9:00 am ET in New York City.

A live audio webcast of the presentation will be available on the Investors section of the company's website, <a href="https://www.alnylam.com">www.alnylam.com</a>. A replay will be available on the Alnylam website within 48 hours after each event.

## **About Alnylam Pharmaceuticals**

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prizewinning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in latestage development or will be in 2017. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. For more information about our people, science and pipeline, please visit <a href="www.alnylam.com">www.alnylam.com</a> and engage with us on Twitter at @Alnylam.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005199/en/

## Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom, 617-682-4340 (Investors and Media) or Josh Brodsky, 617-551-8276 (Investors)

Source: Alnylam Pharmaceuticals, Inc.

News Provided by Acquire Media